Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Proteostasis Ther (PTI)

Proteostasis Ther (PTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,882
  • Shares Outstanding, K 52,185
  • Annual Sales, $ 5,000 K
  • Annual Income, $ -59,130 K
  • 60-Month Beta 1.21
  • Price/Sales 10.96
  • Price/Cash Flow N/A
  • Price/Book 1.48
Trade PTI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.25
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9384 +16.16%
on 10/30/20
1.1700 -6.84%
on 11/16/20
+0.0300 (+2.83%)
since 10/27/20
3-Month
0.9384 +16.16%
on 10/30/20
1.3700 -20.44%
on 08/28/20
-0.2900 (-21.01%)
since 08/27/20
52-Week
0.8700 +25.29%
on 03/16/20
4.7200 -76.91%
on 12/11/19
-1.3100 (-54.58%)
since 11/27/19

Most Recent Stories

More News
Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm - GLIBA, CBMG, MVC, PTI

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:

GLIBA : 91.31 (+0.30%)
CBMG : 18.70 (+0.32%)
MVC : 8.48 (-0.35%)
PTI : 1.0900 (+3.81%)
WeissLaw LLP Reminds PTI, MVC, and EIDX Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

PTI : 1.0900 (+3.81%)
MVC : 8.48 (-0.35%)
EIDX : 90.00 (+1.45%)
Proteostasis: 3Q Earnings Snapshot

BOSTON (AP) _ Proteostasis Therapeutics Inc. (PTI) on Monday reported a loss of $8.2 million in its third quarter.

PTI : 1.0900 (+3.81%)
Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results

, /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended .

PTI : 1.0900 (+3.81%)
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Investigations; Investors are Encouraged to Contact the Firm - CBMG, MVC, PTI, CGIX

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:

CBMG : 18.70 (+0.32%)
MVC : 8.48 (-0.35%)
PTI : 1.0900 (+3.81%)
CGIX : 2.44 (+3.83%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds BMHC, SFBK, WPX, and PTI Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

BMCH : 49.55 (+1.31%)
SFBK : 43.4500 (+0.46%)
WPX : 7.51 (-2.97%)
PTI : 1.0900 (+3.81%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm - MVC, WPX, PTI, SBPH

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:

MVC : 8.48 (-0.35%)
WPX : 7.51 (-2.97%)
PTI : 1.0900 (+3.81%)
SBPH : 1.2100 (unch)
SHAREHOLDER ALERT: WeissLaw LLP Reminds PTI, BMCH, and MOBL Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

BLDR : 37.93 (+1.61%)
PTI : 1.0900 (+3.81%)
MOBL : 7.03 (unch)
Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy?

Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon.

PTI : 1.0900 (+3.81%)
Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

CI : 212.50 (+2.65%)
DRRX : 1.8200 (-2.15%)
GRFS : 18.69 (+2.64%)
PTI : 1.0900 (+3.81%)
CWBR : 1.3300 (+4.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 1.1567
1st Resistance Point 1.1233
Last Price 1.0900
1st Support Level 1.0433
2nd Support Level 0.9967

See More

52-Week High 4.7200
Fibonacci 61.8% 3.2493
Fibonacci 50% 2.7950
Fibonacci 38.2% 2.3407
Last Price 1.0900
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar